Antibody-drug conjugates (ADCs) NSCLC-derived tumor cells produce IL-18, which is a key factor in driving type 1 (IFNγ-producing) responses of CD8C T-cells with high levels of IL-18 receptor (IL-18R), which are balanced by dysfunctional T-cells with low levels of IL-18R in ADC NSCLC. Here, IL18R1 is linked to neoplasm.